For the quarter ending 2025-09-30, ADMA had -$28,900K decrease in cash & cash equivalents over the period. -$1,075K in free cash flow.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net income | 36,429 | 61,122 |
| Depreciation and amortization | 2,023 | 4,027 |
| Loss on disposal of fixed assets | 0 | 0 |
| Deferred income tax provision | 4,803 | 5,045 |
| Stock-based compensation | 5,047 | 9,587 |
| Amortization of debt discount | 170 | 350 |
| Loss on extinguishment of debt | -2,177 | -1,159 |
| Amortization of license revenue | -36 | -71 |
| Accounts receivable | 27,948 | 59,726 |
| Inventories | 5,203 | 21,229 |
| Prepaid expenses and other current assets | -1,117 | 2,095 |
| Deposits and other assets | -45 | 306 |
| Accounts payable | -4,876 | 9,409 |
| Accrued expenses | -221 | -5,206 |
| Other current and non-current liabilities | -234 | -602 |
| Net cash provided by operating activities | 13,293 | 1,464 |
| Purchase of property and equipment | 14,368 | 7,123 |
| Acquisition of intangible assets | 0 | 124 |
| Net cash used in investing activities | -14,368 | -7,247 |
| Term loan payments-Ares Credit Facility | 32,500 | - |
| Ares revolving facility payments-Ares Credit Facility | 72,500 | - |
| Ares revolving facility proceeds-Ares Credit Facility | 30,000 | - |
| Term loan payments-JPMCredit Facilities | 469 | - |
| Jpm term loan proceeds-JPMCredit Facilities | 75,000 | - |
| Proceeds from issuance on revolver | - | 30,000 |
| Prepayment penalties on repayment of debt | 581 | 450 |
| Taxes paid on vested restricted stock units | 964 | 8,419 |
| Principal payments on term loan | - | 30,000 |
| Debt issuance costs | 2,224 | - |
| Net proceeds from the exercise of stock options | 389 | 2,165 |
| Payment of end of term fee | 938 | 375 |
| Acquisition of treasury stock | 23,038 | - |
| Net cash used in financing activities | -27,825 | -7,079 |
| Net (decrease) increase in cash and cash equivalents | -28,900 | -12,862 |
| Cash and cash equivalents at beginning of period | 103,147 | - |
| Cash and cash equivalents at end of period | 61,385 | - |
ADMA BIOLOGICS, INC. (ADMA)
ADMA BIOLOGICS, INC. (ADMA)